Bacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa

Simple item page
dc.contributor.authorLe Roux D.M.
dc.contributor.authorCotton M.F.
dc.contributor.authorLe Roux S.M.
dc.contributor.authorWhitelaw A.
dc.contributor.authorLombard C.J.
dc.contributor.authorZar H.J.
dc.date.accessioned2011-10-13T16:58:23Z
dc.date.available2011-10-13T16:58:23Z
dc.date.issued2011
dc.description.abstractBacteremia contributes to morbidity of HIV-infected children. In a randomized controlled trial evaluating trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, 47 bacteremias were detected. The incidence rate of bacteremia increased in the first 3 months after starting combination antiretroviral therapy (cART), but decreased by 74% once children were established on cART for more than 3 months. Children should be prioritized for early cART. Copyright © 2011 by Lippincott Williams & Wilkins.
dc.description.versionArticle
dc.identifier.citationPediatric Infectious Disease Journal
dc.identifier.citation30
dc.identifier.citation10
dc.identifier.citationhttp://www.scopus.com/inward/record.url?eid=2-s2.0-80052950552&partnerID=40&md5=b9d9398a50fcbe4a3f6c3d4b3e34b1db
dc.identifier.issn8913668
dc.identifier.other10.1097/INF.0b013e318220a68b
dc.identifier.urihttp://hdl.handle.net/10019.1/16705
dc.subjectAfrica
dc.subjectantiretroviral therapy
dc.subjectbacteremia
dc.subjectchildren
dc.subjectHIV
dc.subjectpreventive therapy
dc.subjecttrimethoprim- sulfamethoxazole
dc.titleBacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications